Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.
Akero Therapeutics (NASDAQ: AKRO) is a clinical-stage biotechnology company pioneering FGF21-based therapies for metabolic diseases including NASH and MASH. This page provides investors and researchers with timely updates on clinical developments, regulatory milestones, and corporate announcements directly from the company.
Access authoritative information on Akero's lead candidate efruxifermin (EFX), including Phase 2b/3 trial progress, peer-reviewed research, and strategic partnerships. Our curated news collection covers essential updates, scientific presentations, and financial reports while maintaining strict compliance with financial disclosure standards.
Key content includes trial result analyses, FDA communications, patent developments, and executive commentary. Bookmark this page for streamlined tracking of Akero's progress in addressing liver fibrosis and metabolic dysfunction through innovative Fc-FGF21 fusion protein therapy.
Akero Therapeutics will host an investor webcast on September 13, 2022, at 8:00 a.m. ET to present clinical data from the Phase 2b HARMONY study. This study assesses the effectiveness of efruxifermin (EFX) in patients with pre-cirrhotic non-alcoholic steatohepatitis (NASH). The trial involved 128 patients and seeks to measure improvements in liver fibrosis and other related health metrics. Despite being a potentially best-in-class treatment for NASH, no approved therapies currently exist for this condition.
Akero Therapeutics (Nasdaq: AKRO) announced promising results from its Phase 2a BALANCED trial on efruxifermin (EFX) for treating non-alcoholic steatohepatitis (NASH) patients with cirrhosis. The results showed that 33% of patients improved by one fibrosis stage without worsening NASH, and 25% achieved NASH resolution. EFX was well-tolerated and led to significant decreases in liver stiffness and serum markers of fibrosis. Upcoming data from the Phase 2b HARMONY and SYMMETRY studies are highly anticipated, further highlighting EFX's potential.
Akero Therapeutics (Nasdaq: AKRO) reported its Q2 2022 results, highlighting a $25 million equity investment from Pfizer and a $100 million loan from Hercules Capital to advance efruxifermin (EFX) development. Cash reserves totaled $180.7 million, expected to fund operations until Q3 2024. Key clinical trial updates include upcoming results from the Phase 2b HARMONY study in September and the SYMMETRY study anticipated in late 2023. Research and development expenses for Q2 were $21.4 million, down from $24 million year-over-year.
Akero Therapeutics (Nasdaq: AKRO) announced promising results from a post hoc analysis of its Phase 2a BALANCED study on efruxifermin (EFX) presented at the 2022 International Liver Congress. The analysis revealed that EFX improved liver histopathology and non-invasive markers in NASH patients, specifically among those carrying the PNPLA3 I148M variant, which significantly increases the risk of disease progression. The study involved 58 patients and suggests EFX's potential to address unmet needs in high-risk NASH patients. EFX is currently under evaluation in two Phase 2b trials, with results expected soon.
Akero Therapeutics (Nasdaq: AKRO) announced a $25 million equity investment from Pfizer at $9.90 per share and a $100 million term loan facility from Hercules Capital. The financing aims to support the ongoing development of efruxifermin (EFX), targeting nonalcoholic steatohepatitis (NASH). If fully drawn, the loan extends Akero's cash runway to Q3 2024, two years beyond the anticipated HARMONY study readout. Pfizer will acquire approximately 6.7% of Akero's shares and join a newly formed Scientific Advisory Board.
Akero Therapeutics (Nasdaq: AKRO) announced it will present findings at the Keystone Symposium on Tissue Fibrosis and Repair, June 12-16, 2022. The presentations will showcase the potential of efruxifermin (EFX) to reverse fibrosis in patients with nonalcoholic steatohepatitis (NASH). Notably, data from the Phase 2a BALANCED trial demonstrates significant reductions in liver collagen synthesis markers. Chief Scientific Officer Tim Rolph emphasized EFX's promise as an antifibrotic therapy, with patients showing substantial improvement after just 16 weeks of treatment.
Akero Therapeutics (Nasdaq: AKRO) announced its participation in the Jefferies Global Healthcare Conference on June 9, 2022, at 4:00 p.m. E.T. This clinical-stage company focuses on innovative treatments for serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), which currently lacks approved therapies. Their lead candidate, efruxifermin (EFX), is designed for convenient weekly subcutaneous dosing and is under evaluation in two Phase 2b clinical trials. The presentation will be webcasted live, with archived replays available on their website.
Akero Therapeutics (Nasdaq: AKRO) is progressing well in its clinical trials for efruxifermin (EFX), targeting non-alcoholic steatohepatitis (NASH). The company reported Q1 2022 financial results, with cash reserves of $165.4 million expected to sustain operations into Q3 2023. Research and development expenses surged to $20.5 million, reflecting ongoing clinical trials. Total operating expenses reached $26.1 million, compared to $15.1 million in Q1 2021. Akero anticipates reporting results from its Phase 2b HARMONY study in Q3 2022.
Akero Therapeutics (Nasdaq: AKRO) announced its participation in two upcoming investor conferences. The BofA Securities 2022 Healthcare Conference includes a fireside chat on May 11 at 8:40 a.m. PT in Las Vegas, while the H.C. Wainwright Annual Global Life Sciences Conference offers on-demand viewing of a fireside chat on May 24 at 7:00 a.m. ET. Webcasts will be accessible on their website, with archived replays available later. Akero is focused on developing innovative treatments for serious metabolic diseases, particularly NASH.
Akero Therapeutics (Nasdaq: AKRO) reported its financial results for the fourth quarter and full year 2021, indicating cash reserves of $188.3 million, sufficient to fund operations into Q3 2023. The company is on track to release results from the Phase 2b HARMONY study for its lead candidate, efruxifermin (EFX), in Q3 2022. Increased R&D expenses of $81.8 million for 2021 are attributed to the EFX program. Akero has made advancements in manufacturing capabilities, including a new drug formulation in a dual-chamber syringe device for self-administration.
FAQ
What is the current stock price of Akero Therapeutics (AKRO)?
What is the market cap of Akero Therapeutics (AKRO)?
